OXFORD ENDOVASCULAR LIMITED

Active Oxford

Research and experimental development on biotechnology

9 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
O

OXFORD ENDOVASCULAR LIMITED

Research and experimental development on biotechnology

Founded 9 Sept 2015 Active Oxford, United Kingdom 9 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 21 Jan 2026 Next due 30 Jun 2027 13 months remaining
Confirmation Submitted 1 Oct 2025 Next due 23 Sept 2026 3 months remaining
Net assets £5M £2M 2025 year on year
Total assets £6M £3M 2025 year on year
Total Liabilities £584K £210K 2025 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

9400 Garsington Road Oxford Business Park Oxford OX4 2HN United Kingdom

Website

www.example.com

Full company profile for OXFORD ENDOVASCULAR LIMITED (09769779), an active life sciences and medical technology company based in Oxford, United Kingdom. Incorporated 9 Sept 2015. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Oct → 30 Sept 2025
Type total-exemption-full
Next accounts 30 Sept 2026
Due by 30 Jun 2027 13 months remaining

Net Assets, Total Assets & Total Liabilities (2016–2025)

Cash in Bank

£5.16M

Decreased by £2.76M (-35%)

Net Assets

£5.27M

Decreased by £2.39M (-31%)

Total Liabilities

£584.30k

Decreased by £210.41k (-26%)

Turnover

N/A

Employees

9

Increased by 3 (+50%)

Debt Ratio

10%

Increased by 1 (+11%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
30 Sept Year End
2024
30 Sept Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 2
Grants 1

Investors (9)

Investor NameInvestor SinceParticipating Rounds
Investor 2Apr 2021Series A
Investor 4Apr 2021Series A
Investor 5Apr 2021Series A

Share Capital

Share Capital

Share allotments and capital structure

12 Allotments 383,526 Shares £15.68m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
2 Jan 20256,000£60£0.01
25 Apr 20243,232£133k£41.16
11 Apr 2024243£10k£41.16
9 Apr 202446,888£1.93m£41.16
3 Apr 20247,701£360k£46.77

Officers

Officers

1 active 2 resigned
Status
Parkwalk Advisors LtdCorporate-directorUnited KingdomUnknown24 Apr 2019Active

Shareholders

Shareholders (26)

Mnl (parkwalk) Nominees Limited A/c Parkwalk
24.6%
183,253
Oxford Science Enterprises Plc
21.0%
156,303

Persons with Significant Control

Persons with Significant Control (1)

1 Active 2 Ceased

Parkwalk Advisors Ltd

United Kingdom

Active
Notified 9 Apr 2024
Nature of Control
  • Voting Rights 25 To 50 Percent
Ceased

Parkwalk Advisors Ltd

Ceased 8 Feb 2024

Ceased

Group Structure

Group Structure

IP GROUP PLC united kingdom
PARKWALK ADVISORS LTD united kingdom
OXFORD ENDOVASCULAR LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
21 Jan 2026AccountsAnnual accounts made up to 30 Sept 2025
1 Oct 2025Confirmation StatementConfirmation statement made on 9 Sept 2025 with updates
3 Jul 2025AccountsAnnual accounts made up to 30 Sept 2024
6 Jan 2025CapitalAllotment of shares (GBP 7,444.53) on 2 Jan 2025
4 Oct 2024OfficersTermination of Michael Karim as director on 30 Sept 2024
21 Jan 2026 Accounts

Annual accounts made up to 30 Sept 2025

1 Oct 2025 Confirmation Statement

Confirmation statement made on 9 Sept 2025 with updates

3 Jul 2025 Accounts

Annual accounts made up to 30 Sept 2024

6 Jan 2025 Capital

Allotment of shares (GBP 7,444.53) on 2 Jan 2025

4 Oct 2024 Officers

Termination of Michael Karim as director on 30 Sept 2024

Recent Activity

Latest Activity

Annual accounts made up to 30 Sept 2025

4 months ago on 21 Jan 2026

Confirmation statement made on 9 Sept 2025 with updates

8 months ago on 1 Oct 2025

Annual accounts made up to 30 Sept 2024

11 months ago on 3 Jul 2025

Allotment of shares (GBP 7,444.53) on 2 Jan 2025

1 years ago on 6 Jan 2025

Termination of Michael Karim as director on 30 Sept 2024

1 years ago on 4 Oct 2024